Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for elderly lymphoma patients who Can't tolerate chemo

NCT ID NCT05952024

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 24 times

Summary

This study tests a combination of two drugs, acalabrutinib and rituximab, in patients aged 80 and older or those 65-79 who are too frail for standard chemotherapy. The goal is to see if this treatment is safe and effective for controlling diffuse large B-cell lymphoma. About 80 participants will receive the drugs, and researchers will monitor side effects and how well the cancer responds.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    WITHDRAWN

    Berkeley, California, 94704, United States

  • Research Site

    COMPLETED

    La Jolla, California, 92093, United States

  • Research Site

    RECRUITING

    Orange, California, 92868, United States

  • Research Site

    WITHDRAWN

    Stamford, Connecticut, 06902, United States

  • Research Site

    ACTIVE_NOT_RECRUITING

    Jacksonville, Florida, 32256, United States

  • Research Site

    RECRUITING

    Des Moines, Iowa, 50309, United States

  • Research Site

    WITHDRAWN

    Lexington, Kentucky, 40536, United States

  • Research Site

    ACTIVE_NOT_RECRUITING

    Beltsville, Maryland, 20705, United States

  • Research Site

    ACTIVE_NOT_RECRUITING

    Towson, Maryland, 21204, United States

  • Research Site

    ACTIVE_NOT_RECRUITING

    Detroit, Michigan, 48202, United States

  • Research Site

    WITHDRAWN

    Sioux Falls, South Dakota, 57104, United States

  • Research Site

    ACTIVE_NOT_RECRUITING

    Lubbock, Texas, 79410, United States

  • Research Site

    ACTIVE_NOT_RECRUITING

    Olympia, Washington, 98506, United States

  • Research Site

    RECRUITING

    Tacoma, Washington, 98405, United States

  • Research Site

    ACTIVE_NOT_RECRUITING

    Barretos, 14784-400, Brazil

  • Research Site

    ACTIVE_NOT_RECRUITING

    Belo Horizonte, 30150-221, Brazil

  • Research Site

    ACTIVE_NOT_RECRUITING

    Brasília, 70200-730, Brazil

  • Research Site

    RECRUITING

    Brasília, 70390-700, Brazil

  • Research Site

    ACTIVE_NOT_RECRUITING

    Brasília, 70840-901, Brazil

  • Research Site

    ACTIVE_NOT_RECRUITING

    Campinas, 13060-803, Brazil

  • Research Site

    ACTIVE_NOT_RECRUITING

    Curitiba, 81520-060, Brazil

  • Research Site

    ACTIVE_NOT_RECRUITING

    Florianópolis, 88020-210, Brazil

  • Research Site

    RECRUITING

    Florianópolis, 88034-000, Brazil

  • Research Site

    ACTIVE_NOT_RECRUITING

    Goiânia, 74605-020, Brazil

  • Research Site

    ACTIVE_NOT_RECRUITING

    Natal, 59075-740, Brazil

  • Research Site

    ACTIVE_NOT_RECRUITING

    Porto Alegre, 90035-003, Brazil

  • Research Site

    ACTIVE_NOT_RECRUITING

    Porto Alegre, 90880-480, Brazil

  • Research Site

    ACTIVE_NOT_RECRUITING

    Recife, 50070-480, Brazil

  • Research Site

    ACTIVE_NOT_RECRUITING

    Ribeirão Preto, 14048-900, Brazil

  • Research Site

    ACTIVE_NOT_RECRUITING

    Rio de Janeiro, 20231-050, Brazil

  • Research Site

    RECRUITING

    São José do Rio Preto, 15090-000, Brazil

  • Research Site

    ACTIVE_NOT_RECRUITING

    São Luís, 65060-645, Brazil

  • Research Site

    ACTIVE_NOT_RECRUITING

    São Paulo, 01229-010, Brazil

  • Research Site

    ACTIVE_NOT_RECRUITING

    São Paulo, 01409-02, Brazil

  • Research Site

    ACTIVE_NOT_RECRUITING

    São Paulo, 05652-900, Brazil

  • Research Site

    COMPLETED

    São Paulo, 08270-070, Brazil

  • Research Site

    ACTIVE_NOT_RECRUITING

    São Paulo, 1323000, Brazil

  • Research Site

    ACTIVE_NOT_RECRUITING

    Sorocaba, 18030-005, Brazil

  • Research Site

    ACTIVE_NOT_RECRUITING

    San Juan, 00917, Puerto Rico

  • Research Site

    RECRUITING

    Busan, 47392, South Korea

  • Research Site

    ACTIVE_NOT_RECRUITING

    Busan, 49241, South Korea

  • Research Site

    ACTIVE_NOT_RECRUITING

    Daegu, 42601, South Korea

  • Research Site

    ACTIVE_NOT_RECRUITING

    Gyeongsangnam-do, 52727, South Korea

  • Research Site

    ACTIVE_NOT_RECRUITING

    Incheon, 405-760, South Korea

  • Research Site

    ACTIVE_NOT_RECRUITING

    Jeonju, 54907, South Korea

  • Research Site

    ACTIVE_NOT_RECRUITING

    Seogu, 49201, South Korea

  • Research Site

    ACTIVE_NOT_RECRUITING

    Seoul, 03722, South Korea

  • Research Site

    ACTIVE_NOT_RECRUITING

    Seoul, 05505, South Korea

  • Research Site

    ACTIVE_NOT_RECRUITING

    Seoul, 06351, South Korea

  • Research Site

    RECRUITING

    Seoul, 06591, South Korea

  • Research Site

    ACTIVE_NOT_RECRUITING

    Seoul, 07985, South Korea

  • Research Site

    ACTIVE_NOT_RECRUITING

    Suwon, 16499, South Korea

  • Research Site

    ACTIVE_NOT_RECRUITING

    Ulsan, 44033, South Korea

  • Research Site

    WITHDRAWN

    Kaohsiung City, 80756, Taiwan

  • Research Site

    WITHDRAWN

    Kaohsiung City, 833, Taiwan

  • Research Site

    WITHDRAWN

    Tainan, 736, Taiwan

  • Research Site

    WITHDRAWN

    Taipei, 100, Taiwan

Conditions

Explore the condition pages connected to this study.

DIFFUSE LARGE B-CELL LYMPHOMA